| Patents v. Statutory Exclusivities in Biological Pharmaceuticals-Do We Really Need Both Y Heled Mich. Telecomm. & Tech. L. Rev. 18, 419, 2011 | 91 | 2011 |
| Regulatory competitive shelters Y Heled Ohio St. LJ 76, 299, 2015 | 53 | 2015 |
| The problem with relying on profit-driven models to produce pandemic drugs Y Heled, AS Rutschman, L Vertinsky Journal of Law and the Biosciences 7 (1), lsaa060, 2020 | 36 | 2020 |
| The Regulation of Genetic Aspects of Donated Reproductive Tissue-The Need for Federal Regulation Y Heled Colum. Sci. & Tech. L. Rev. 11, 243, 2010 | 34 | 2010 |
| Why Healthcare Companies Should Be (come) Benefit Corporations Y Heled, L Vertinsky, C Brewer BCL Rev. 60, 73, 2019 | 31 | 2019 |
| The case for disclosure of biologics manufacturing information Y Heled Journal of Law, Medicine & Ethics 47 (S4), 54-78, 2019 | 21 | 2019 |
| On patenting human organisms or how the abortion wars feed into the ownership fallacy Y Heled Cardozo L. Rev. 36, 241, 2014 | 20 | 2014 |
| Why primary patents covering biologics should be unforceable against generic applicants under the Biologics Price Competition and Innovation Act Y Heled Annals Health L. 21, 211, 2012 | 16 | 2012 |
| Genetic Paparazzi: Beyond Genetic Privacy Y Heled, L Vertinsky Ohio St. LJ 82, 409, 2021 | 8 | 2021 |
| On presidents, agencies, and the stem cells between them: A legal analysis of president Bush's and the federal government's policy on the funding of research involving human … Y Heled Admin. L. Rev. 60, 65, 2008 | 8 | 2008 |
| A Wrong Without a Remedy: Leaving Parents and Children with a Hollow Victory in Lawsuits Against Unscrupulous Sperm Banks Y Heled, T Lytton, L Vertinsky Chi.-Kent L. Rev. 96, 115, 2021 | 6 | 2021 |
| Regulatory Reactivity Y Heled, AS Rutschman, L Vertinsky Food and Drug Law Journal 76 (2), 318-336, 2021 | 6 | 2021 |
| Follow-On Biologics Are Set Up to Fail Y Heled U. Ill. L. Rev. Online, 113, 2018 | 6 | 2018 |
| Regulatory Competitive Shelters'(2015) Y Heled Ohio State Law Journal 76, 299, 0 | 6 | |
| The Biologics Price Competition and Innovation Act at 10-A Stocktaking Y Heled Tex. A&M J. Prop. L. 7, 81, 2021 | 5 | 2021 |
| Regulatory Competitive Shelters in the Area of Personalized Medicine Y Heled BUJ Sci. & Tech. L. 21, 287, 2015 | 5 | 2015 |
| Patents vs. Statutory Exclusivities in Biological Pharmaceuticals–Do We Really Need Both?’(2012) Y Heled Michigan Telecommunications and Technology Law Review 18, 419, 0 | 5 | |
| Intellectual Property and Public Health–A White Paper RG Vacca, JM Chen, J Dratler, T Folsom, TS Hall, Y Heled, F Pasquale, ... Akron Intellectual Property Journal 7, 13-11, 2013 | 4 | 2013 |
| Response to ‘pervasive sequence patents cover the entire human genome’ S Tu, C Holman, A Mossoff, T Sichelman, M Risch, JL Conteras, Y Heled, ... Genome medicine 6, 1-3, 2014 | 3 | 2014 |
| Righting a reproductive wrong: a statutory tort solution to misrepresentation by reproductive tissue providers Y Heled, HY Levin, TD Lytton, L Vertinsky Hous. L. Rev. 60, 1, 2022 | 2 | 2022 |
